Future Planet Capital

A UK-based educational tour operator specializing in cultural and historical trips for schools and colleges across Europe. Headquartered in Birmingham, their multilingual team focuses on delivering high-quality experiences at competitive prices.

Midven, established in 1990 and headquartered in Birmingham, UK, is a venture capital firm specialising in early-stage and growth-stage investments. It focuses on providing up to £1 million to fast-growing small and medium-sized enterprises (SMEs), supporting their expansion and development. Midven's team, comprising experienced and hands-on investment managers, offers not only capital but also strategic guidance to its portfolio companies.

Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

Linear Diagnostics develops a proprietary diagnostic platform technology that enables rapid, simultaneous detection of multiple targets using a single reagent. Its core innovation, linear dichroism, facilitates molecular diagnostics tests across various sectors, including infectious diseases and food safety.

A UK-based educational tour operator specializing in cultural and historical trips for schools and colleges across Europe. Headquartered in Birmingham, their multilingual team focuses on delivering high-quality experiences at competitive prices.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

A UK-based educational tour operator specializing in cultural and historical trips for schools and colleges across Europe. Headquartered in Birmingham, their multilingual team focuses on delivering high-quality experiences at competitive prices.

Etive Technologies Limited specializes in providing digital data handling solutions focused on personal and property information through a range of web-based log book products. The company's offerings include the Digital Log Book, which helps individuals create a digital identity, and the Home Log Book, designed to enhance the buying process for new home developers by providing essential information and improving post-occupancy customer service. Additionally, the Energy Log Book allows users to monitor and manage home energy consumption. Etive serves a diverse clientele, including local authorities, housing associations, new home builders, healthcare providers, financial service companies, and estate agencies. Founded in 2011 and based in Edinburgh, with an additional office in Birmingham, the company was previously known as Home Log Book Solutions Limited before rebranding in December 2013.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

A UK-based educational tour operator specializing in cultural and historical trips for schools and colleges across Europe. Headquartered in Birmingham, their multilingual team focuses on delivering high-quality experiences at competitive prices.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.